Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
Publication
, Journal Article
Heymach, JV; Harpole, D; Reck, M
Published in: N Engl J Med
January 18, 2024
Duke Scholars
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
January 18, 2024
Volume
390
Issue
3
Start / End Page
287 / 288
Location
United States
Related Subject Headings
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Heymach, J. V., Harpole, D., & Reck, M. (2024). Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply. N Engl J Med, 390(3), 287–288. https://doi.org/10.1056/NEJMc2313778
Heymach, John V., David Harpole, and Martin Reck. “Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.” N Engl J Med 390, no. 3 (January 18, 2024): 287–88. https://doi.org/10.1056/NEJMc2313778.
Heymach JV, Harpole D, Reck M. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply. N Engl J Med. 2024 Jan 18;390(3):287–8.
Heymach, John V., et al. “Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.” N Engl J Med, vol. 390, no. 3, Jan. 2024, pp. 287–88. Pubmed, doi:10.1056/NEJMc2313778.
Heymach JV, Harpole D, Reck M. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply. N Engl J Med. 2024 Jan 18;390(3):287–288.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
January 18, 2024
Volume
390
Issue
3
Start / End Page
287 / 288
Location
United States
Related Subject Headings
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Carcinoma, Non-Small-Cell Lung
- Antibodies, Monoclonal
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences